Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC)
$1.73
-0.0100 ( -0.57% ) 55.1K
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Market Data
Open
$1.73
Previous close
$1.74
Volume
55.1K
Market cap
$2.56M
Day range
$1.72 - $1.78
52 week range
$1.30 - $13.20
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 63 | Nov 29, 2023 |
10-k/a | Quarterly Reports | 95 | Nov 29, 2023 |
8-k | 8K-related | 13 | Nov 28, 2023 |
nt | Quarterly Reports | 1 | Nov 15, 2023 |
8-k | 8K-related | 13 | Nov 15, 2023 |
def | Proxies and info statements | 3 | Nov 14, 2023 |
8-k | 8K-related | 16 | Nov 13, 2023 |
8-k | 8K-related | 14 | Nov 07, 2023 |
pre | Proxies and info statements | 3 | Nov 02, 2023 |
8-k | 8K-related | 13 | Sep 08, 2023 |